FluoroquinoloneSTICKERNCT07361185
A Sticker Reminder Intervention to Promote IV-to-PO Fluoroquinolone Switching
A study testing Sticker reminder in people with Fluoroquinolone and Adult, run by Mahidol University at 1 site in Thailand.
Trial summary
A single-center, cluster-randomized controlled trial was conducted to determine the effect of Sticker reminder intervention on IV-to-PO switching of fluoquinolone. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Fluoroquinolone, Adult
- What is being tested?
- Sticker reminder
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 168 participants
- Where
- 1 siteThailand
- Study dates
- 1 Jul 2020to 31 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients (aged ≥ 18 years)
- Diagnosis of any infection
- Receiving at least one dose of intravenous fluoroquinolones (ciprofloxacin, levofloxacin, or moxifloxacin)
Who cannot join
- Inability to tolerate oral medications (e.g., due to severe nausea/vomiting, malabsorption, active gastrointestinal bleeding, or severe diarrhea);
- Being in an immunodeficiency state (e.g., neutropenia [absolute neutrophil count ≤ 500 cells/mm3], symptomatic HIV/AIDS, history of bone marrow or organ transplantation, leukemia, or current use of immunosuppressive agents); or
- Having severe infections requiring exclusive intravenous antimicrobial therapy (e.g., infective endocarditis, meningitis, encephalitis, brain abscess, or prosthetic device infections).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Sticker Reminder Intervention to Promote Intravenous-to-Oral Fluoroquinolone Switching: A Cluster-Randomized Controlled Trial
A single-center, cluster-randomized controlled trial was conducted to determine the effect of Sticker reminder intervention on IV-to-PO switching of fluoquinolone.
Read the detailed description
A single-center, cluster-randomized controlled trial was conducted across 44 general wards at Siriraj Hospital, Thailand, from July 2020 to December 2024. The study population consisted of adult patients who received at least one dose of intravenous fluoroquinolones. Wards were randomized in a 1:1 ratio to either the sticker reminder intervention or standard care. In the intervention group, a reminder sticker was applied to patients' vital signs sheets when predefined IV-to-oral switching criteria were met. The primary outcome was the proportion of intravenous-to-oral fluoroquinolone switching in the intention-to-treat (ITT) and modified intention-to-treat (mITT) populations.
- Conditions
- Fluoroquinolone, Adult
- Being tested
- Sticker reminder
- Keywords
- Antimicrobial stewardship, Fluoroquinolone, Antibiotic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sticker reminderBehavioural
a reminder sticker was applied to the vital signs sheet of patients meeting predefined switching criteria
| Study group | Role | What they receive |
|---|---|---|
| Standard of care | No intervention | No AMs intervention |
| Sticker reminder arm | Experimental | Sticker reminder Receives: Behavioral: Sticker reminder |
What is being measured
The primary outcome is the main question the study is designed to answer.
IV-to-PO switching
Proportion of patients who underwent switching from intravenous fluoroquinolone to oral fluoroquinolone within the same hospitalization
Measured: From the day of initiation of fluoroquinolone to the discharge date (Up to 1 year)
Secondary outcomes (2)
Length of stay
The total length of hospital stay of that given admission
Measured: From the day of initiation of intravenous fluroquinolone to the day of discharge (up to 1 year)
Duration of FQ therapy
The total duration of intravenous fluroquinolone and oral fluroquinolone (day)
Measured: From the first day to the last day of fluroquinolone use (up to 1 year)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2026
- Study start1 Jul 2020
- Primary completion31 Dec 2024
- Study completion31 Dec 2024
Why it stopped: Slow recruitment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for FluoroquinoloneStudies of the same condition, open and under way.
- More trials run by Mahidol UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 168 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mahidol University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07361185
- Sponsor's protocol ID
- 373/2563(IRB1)
- Acronym
- STICKER
- Status last verified
- Jan 2026
- First submitted
- 4 Jan 2026
- Last updated
- 22 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Sakchainan J, Tunprayoon S, Samanloh S, Rattanaumpawan P. A sticker reminder intervention to promote intravenous-to-oral fluoroquinolone conversion: a cluster-randomized controlled trial. BMC Infect Dis. 2026 Jul 7. doi: 10.1186/s12879-026-13937-9. Online ahead of print.
PubMed 42414937
Study at a glance
From the registry record, last updated by the sponsor on 22 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Sticker Reminder Intervention to Promote Intravenous-to-Oral Fluoroquinolone Switching: A Cluster-Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07361185
- Acronym / sponsor ID
- STICKER / 373/2563(IRB1)
- Conditions
- Fluoroquinolone, Adult
- Keywords
- Antimicrobial stewardship, Fluoroquinolone, Antibiotic
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Slow recruitment
- Enrolment
- 168 participants (actual)
- Lead sponsor
- Mahidol UniversityUniversity, hospital or other
- Study start
- 1 Jul 2020 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 22 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A single-center, cluster-randomized controlled trial was conducted to determine the effect of Sticker reminder intervention on IV-to-PO switching of fluoquinolone.
Detailed description
A single-center, cluster-randomized controlled trial was conducted across 44 general wards at Siriraj Hospital, Thailand, from July 2020 to December 2024. The study population consisted of adult patients who received at least one dose of intravenous fluoroquinolones. Wards were randomized in a 1:1 ratio to either the sticker reminder intervention or standard care. In the intervention group, a reminder sticker was applied to patients' vital signs sheets when predefined IV-to-oral switching criteria were met. The primary outcome was the proportion of intravenous-to-oral fluoroquinolone switching in the intention-to-treat (ITT) and modified intention-to-treat (mITT) populations.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard of care | No intervention | –No AMs intervention |
| Sticker reminder arm | Experimental | Behavioral: Sticker reminderSticker reminder |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adult patients (aged ≥ 18 years)
- Diagnosis of any infection
- Receiving at least one dose of intravenous fluoroquinolones (ciprofloxacin, levofloxacin, or moxifloxacin)
Key exclusion criteria (3 listed)
- Inability to tolerate oral medications (e.g., due to severe nausea/vomiting, malabsorption, active gastrointestinal bleeding, or severe diarrhea);
- Being in an immunodeficiency state (e.g., neutropenia [absolute neutrophil count ≤ 500 cells/mm3], symptomatic HIV/AIDS, history of bone marrow or organ transplantation, leukemia, or current use of immunosuppressive agents); or
- Having severe infections requiring exclusive intravenous antimicrobial therapy (e.g., infective endocarditis, meningitis, encephalitis, brain abscess, or prosthetic device infections).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sticker remindera reminder sticker was applied to the vital signs sheet of patients meeting predefined switching criteria | Behavioural | Sticker reminder arm |
Primary outcome
IV-to-PO switching
Time frame: From the day of initiation of fluoroquinolone to the discharge date (Up to 1 year)
Proportion of patients who underwent switching from intravenous fluoroquinolone to oral fluoroquinolone within the same hospitalization
2 secondary outcomes
Length of stay
Time frame: From the day of initiation of intravenous fluroquinolone to the day of discharge (up to 1 year)
Duration of FQ therapy
Time frame: From the first day to the last day of fluroquinolone use (up to 1 year)
Results and safety
The study was stopped early (reason given: Slow recruitment). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jan 2026.
- Derived from this study: PubMed 42414937Sakchainan J, Tunprayoon S, Samanloh S, Rattanaumpawan P. A sticker reminder intervention to promote intravenous-to-oral fluoroquinolone conversion: a cluster-randomized controlled trial. BMC Infect Dis. 2026 Jul 7. doi: 10.1186/s12879-026-13937-9. Online ahead of print.
- Individual participant dataSharing planned: No
Related trials for Fluoroquinolone
RecruitingPhase 3
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
Not yet recruiting
Fluoroquinolone-Doxycycline Oral Treatments for Adults With Uncomplicated Brucellosis
Brucellosis
Not yet recruiting
All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular Brucellosis
Brucellosis, Osteoarticular Brucellosis
RecruitingPhase 1/2
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
E Coli Infections, Allogenic Transplant Patients
RecruitingObservational study
Bioneer Q-RFIA Clinical Evaluation
Tuberculosis, Multidrug-Resistant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sticker reminder in people with Fluoroquinolone and Adult, run by Mahidol University at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 22 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Slow recruitment). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
IV-to-PO switching (time frame: From the day of initiation of fluoroquinolone to the discharge date (Up to 1 year)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07361185, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2026.